Exhibit 99.1

          Interleukin Genetics Announces the Departure of Two Directors
                      and the Appointment of One Director

    WALTHAM, Mass.--(BUSINESS WIRE)--Sept. 20, 2004--Interleukin
Genetics, Inc. (OTCBB: ILGN) announced today that two directors
elected by Pyxis Innovations, Inc. (Pyxis), a subsidiary of Alticor
and the sole holder of Interleukin's Series A Preferred Stock, have
resigned from the Board of Directors and that Pyxis has nominated one
new director.
    On September 14, 2004, Bert Crandell and Beto Guajardo resigned
from our Board of Directors. Both of the directors had been elected by
Pyxis in accordance with our Certificate of Incorporation, as amended,
under which they have the right to appoint four out of five members of
our Board of Directors. On September 15, 2004, Pyxis elected Mr.
William J. Viveen, Jr. to the Board of Directors. Mr. Viveen is Vice
President Finance and Corporate Controller of Alticor, Inc., an
affiliate of Pyxis. Mr. Viveen will also succeed Mr. Guajardo as a
member of our Audit Committee.
    "We would like to express our thanks to Bert and Beto for their
contributions to the Board since their election and simultaneously
extend a warm welcome to Bill Viveen to our Board" said Philip R.
Reilly, MD, JD, Interleukin's Chairman and Chief Executive Officer.
"We look forward to continuing our excellent working relationship with
Alticor."

    About Interleukin

    Interleukin Genetics is a biotechnology company focused on
developing personalized health products. The company uses functional
genomics to help in the development of risk assessment tests,
pharmacogenetic tests, nutritional and therapeutic products based on
the genetic variations in people. Interleukin's current programs focus
on cardiovascular disease, osteoporosis, rheumatoid arthritis,
endometriosis, periodontal disease and weight management. Interleukin
expects that these programs will lead to products that will
personalize the selection of nutritional and therapeutic products and
enable the managed care industry to improve patient care and better
allocate resources. For more information about Interleukin and its
ongoing programs, please visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding our ability to develop
diagnostic, personalized nutritional and therapeutic products to
prevent or treat diseases of inflammation and other genetic
variations, our ability to screen nutritional compounds for their
effects on inflammatory responses and other genetic variations, given
specific genetic patterns and our ability to make progress in
advancing our core technologies. Because such statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Factors that
could cause actual results to differ materially from those expressed
or implied by such forward-looking statements include, but are not
limited to, our ability to develop diagnostic, personalized
nutritional and therapeutic products to prevent or treat diseases of
inflammation and other genetic variations, our ability to screen
nutritional compounds for their effects on inflammatory responses and
other genetic variations, given specific genetic patterns, our ability
to construct a DNA testing laboratory, our ability to complete all of
our key milestones with regard to Alticor programs, our ability to
make progress in advancing our core technologies and our ability to
launch new commercial products and those risks and uncertainties
described in our annual report on Form 10-K, our quarterly reports on
Form 10-Q and in other filings made by us with the Securities and
Exchange Commission. We disclaim any obligation or intention to update
these forward-looking statements.

    CONTACT: Interleukin Genetics
             Fenel M. Eloi, 781-398-0700